WallStSmart

Globus Medical (GMED)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 722% more annual revenue ($25.84B vs $3.14B). GMED leads profitability with a 17.0% profit margin vs 14.4%. SYK appears more attractively valued with a PEG of 1.15. SYK earns a higher WallStSmart Score of 67/100 (B-).

GMED

Buy

60

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.7Quality: 9.5
Piotroski: 6/9Altman Z: 5.43

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GMEDUndervalued (+37.2%)

Margin of Safety

+37.2%

Fair Value

$140.62

Current Price

$74.19

$66.43 discount

UndervaluedFair: $140.62Overvalued
SYKSignificantly Overvalued (-19.9%)

Margin of Safety

-19.9%

Fair Value

$229.73

Current Price

$275.56

$45.83 premium

UndervaluedFair: $229.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GMED4 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.4310/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.8%8/10

Strong operational efficiency at 24.8%

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$105.70B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

GMED2 concerns · Avg: 3.0/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

EPS GrowthGrowth
-26.2%2/10

Earnings declined 26.2%

SYK2 concerns · Avg: 3.5/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : GMED

The strongest argument for GMED centers on Debt/Equity, Altman Z-Score, Price/Book. Profitability is solid with margins at 17.0% and operating margin at 24.8%.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : GMED

The primary concerns for GMED are PEG Ratio, EPS Growth.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

GMED profiles as a mature stock while SYK is a value play — different risk/reward profiles.

GMED carries more volatility with a beta of 0.96 — expect wider price swings.

SYK is growing revenue faster at 9.4% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (67/100 vs 60/100). GMED offers better value entry with a 37.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Globus Medical

HEALTHCARE · MEDICAL DEVICES · USA

Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?